Related Experiment Video
Updated: May 4, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
[Current status and issues of clinical development of novel anti-diabetic drugs]
1Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School.
Abstract:
Clinical development of new antidiabetic drugs such as SGLT2 inhibitor, GPR40 agonist, GPR119 agonist, and GKA has been progressing world wide. Action mechanism of each drug is unique and clearly distinguished from the existing drugs. The effect of SGLT2 inhibitors is independent of insulin action and characterized by inhibition of glucose reabsorption in the kidney accompanying with significant body weight reduction. It is known that GPR40 agonist stimulates insulin secretion in glucose independent manner. GKA potentiates glucose-stimulated insulin secretion from pancreatic beta cells and stimulates glucose uptake into the liver. Selective SGLT2 inhibitors and GPR40 agonist are expected to enter into the market in near future.
Related Concept Videos
Type I Diabetes III: Clinical Manifestations
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Clinical Trials: Overview
Preclinical Development: Overview
Diabetes Mellitus: Introduction

